Monday, 28 September 2026Updated 7m ago
Litmus Paper

Indian business & markets · every report, clustered into stories and tested for tone

NSE close · Fri, 25 SeptNifty 5023,140.50▲ 0.34%Nifty Bank55,580.40▲ 0.26%Midcap 10060,906.00▼ 0.14%Smallcap 25018,158.900.02%India VIX12.16▼ 4.18%IT28,160.90▼ 0.17%Auto26,967.90▲ 0.89%Pharma27,003.00▼ 0.10%FMCG45,941.30▲ 0.40%Metal13,087.15▲ 0.35%Realty869.35▲ 0.92%Energy37,440.35▲ 0.21%PSU Bank8,294.50▲ 0.28%Financials25,094.85▲ 0.56%Media1,550.65▼ 0.23%Defence9,401.65▲ 0.43%Durables38,278.60▲ 0.95%Biggest movesTURTLEMINT▼ 20.0%ADSL▲ 20.0%HEROMOTORS▲ 20.0%SHANTIGOLD▲ 14.8%UGARSUGAR▲ 14.8%MAWANASUG▲ 14.5%TGVSL▲ 14.2%UTTAMSUGAR▲ 12.7%

Market pulse

325 tags with 2 or more stories in the last 24 hours
bearishbullish

Top stories

890 today · ranked by importance and coverage
Expansion▲Picking up

Godrej Properties and MICL plan ₹6,000 crore Marine Lines project

  • The luxury residential project covers a 2.5-acre site in Marine Lines, South Mumbai
  • The project has estimated revenue potential of ₹6,000 crore
  • MICL transferred development rights to Godrej Properties; the rights were jointly held with Shreepati Group
  • The project adds a major Mumbai launch for Godrej Properties and a development-rights transaction for MICL
Deal▲Picking up

Sun Pharma secures rights to commercialise Lerodalcibep outside the US and China

  • Sun Pharma will commercialise and manufacture Lerodalcibep worldwide, excluding the United States and China
  • The once-monthly PCSK9 inhibitor treats adults with high LDL cholesterol
  • LIB Therapeutics will receive upfront and milestone payments plus royalties on net sales
  • The licensing deal expands Sun Pharma’s cardiovascular pipeline and potential sales beyond the US and China
770 more in Latest